Fig. 4

The effect of the PARP inhibitor, olaparib, and doxorubicin on the proliferation of osteosarcoma cells. Treatment with the PARP inhibitor, olaparib (a), and doxorubicin (b) significantly inhibited the growth of U2OS, SaOS2, MG63, and KHOS/NP osteosarcoma cells in a dose- and time-dependent manner. At the end of treatment, the cell viability was measured by an MTT assay. *, versus control, P < 0.05; **, versus control, P < 0.001